CAI
Price
$27.24
Change
+$1.13 (+4.33%)
Updated
Dec 3 closing price
Capitalization
7.69B
83 days until earnings call
Intraday BUY SELL Signals
CRDF
Price
$2.13
Change
+$0.09 (+4.41%)
Updated
Dec 3 closing price
Capitalization
143.48M
84 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CAI vs CRDF

Header iconCAI vs CRDF Comparison
Open Charts CAI vs CRDFBanner chart's image
Caris Life Sciences
Price$27.24
Change+$1.13 (+4.33%)
Volume$3.1M
Capitalization7.69B
Cardiff Oncology
Price$2.13
Change+$0.09 (+4.41%)
Volume$837.66K
Capitalization143.48M
CAI vs CRDF Comparison Chart in %
CAI
Daily Signal:
Gain/Loss:
CRDF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CAI vs. CRDF commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CAI is a StrongBuy and CRDF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (CAI: $26.13 vs. CRDF: $2.04)
Brand notoriety: CAI and CRDF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CAI: 348% vs. CRDF: 74%
Market capitalization -- CAI: $7.69B vs. CRDF: $143.48M
CAI [@Biotechnology] is valued at $7.69B. CRDF’s [@Biotechnology] market capitalization is $143.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CAI’s FA Score shows that 1 FA rating(s) are green whileCRDF’s FA Score has 0 green FA rating(s).

  • CAI’s FA Score: 1 green, 4 red.
  • CRDF’s FA Score: 0 green, 5 red.
According to our system of comparison, CAI is a better buy in the long-term than CRDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CAI’s TA Score shows that 5 TA indicator(s) are bullish while CRDF’s TA Score has 6 bullish TA indicator(s).

  • CAI’s TA Score: 5 bullish, 3 bearish.
  • CRDF’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, CRDF is a better buy in the short-term than CAI.

Price Growth

CAI (@Biotechnology) experienced а +2.13% price change this week, while CRDF (@Biotechnology) price change was -3.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

CAI is expected to report earnings on Feb 25, 2026.

CRDF is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CAI($7.69B) has a higher market cap than CRDF($143M). CRDF (-52.995) and CAI (-53.348) have similar YTD gains . CRDF has higher annual earnings (EBITDA): -53.95M vs. CAI (-186.94M). CAI has more cash in the bank: 721M vs. CRDF (71M). CRDF has less debt than CAI: CRDF (1.19M) vs CAI (419M). CAI has higher revenues than CRDF: CAI (534M) vs CRDF (545K).
CAICRDFCAI / CRDF
Capitalization7.69B143M5,375%
EBITDA-186.94M-53.95M347%
Gain YTD-53.348-52.995101%
P/E RatioN/AN/A-
Revenue534M545K97,982%
Total Cash721M71M1,015%
Total Debt419M1.19M35,359%
FUNDAMENTALS RATINGS
CAI vs CRDF: Fundamental Ratings
CAI
CRDF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
2
Undervalued
55
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9061
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CAI's Valuation (2) in the Finance Or Rental Or Leasing industry is somewhat better than the same rating for CRDF (55) in the null industry. This means that CAI’s stock grew somewhat faster than CRDF’s over the last 12 months.

CAI's Profit vs Risk Rating (100) in the Finance Or Rental Or Leasing industry is in the same range as CRDF (100) in the null industry. This means that CAI’s stock grew similarly to CRDF’s over the last 12 months.

CRDF's SMR Rating (98) in the null industry is in the same range as CAI (100) in the Finance Or Rental Or Leasing industry. This means that CRDF’s stock grew similarly to CAI’s over the last 12 months.

CRDF's Price Growth Rating (61) in the null industry is in the same range as CAI (90) in the Finance Or Rental Or Leasing industry. This means that CRDF’s stock grew similarly to CAI’s over the last 12 months.

CRDF's P/E Growth Rating (100) in the null industry is in the same range as CAI (100) in the Finance Or Rental Or Leasing industry. This means that CRDF’s stock grew similarly to CAI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CAICRDF
RSI
ODDS (%)
Bullish Trend 7 days ago
90%
Bullish Trend 7 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
50%
Bearish Trend 7 days ago
90%
Momentum
ODDS (%)
Bullish Trend 7 days ago
49%
Bullish Trend 7 days ago
80%
MACD
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 7 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
8%
Bullish Trend 7 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
66%
Bearish Trend 7 days ago
88%
Advances
ODDS (%)
Bullish Trend 10 days ago
60%
Bullish Trend 9 days ago
86%
Declines
ODDS (%)
Bearish Trend 18 days ago
61%
Bearish Trend 15 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
50%
Bullish Trend 7 days ago
89%
Aroon
ODDS (%)
Bearish Trend 7 days ago
83%
Bearish Trend 7 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
CAI
Daily Signal:
Gain/Loss:
CRDF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DISCX22.65N/A
N/A
BNY Mellon International Stock Fund C
MRLTX19.57N/A
N/A
AMG Renaissance Large Cap Growth N
SGQIX45.65N/A
N/A
DWS International Opportunities Inst
TIISX13.79N/A
N/A
Nuveen Quant Intl Small Cap Eq R6
FCTDX19.82N/A
N/A
Strategic Advisers Fidelity US TtlStk

CAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, CAI has been loosely correlated with BMEA. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if CAI jumps, then BMEA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CAI
1D Price
Change %
CAI100%
+0.29%
BMEA - CAI
35%
Loosely correlated
-5.22%
VTGN - CAI
23%
Poorly correlated
-18.74%
CRDF - CAI
21%
Poorly correlated
-5.99%
LIXT - CAI
20%
Poorly correlated
-0.98%
PROK - CAI
20%
Poorly correlated
N/A
More

CRDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with NAMS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then NAMS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
-5.99%
NAMS - CRDF
47%
Loosely correlated
-3.23%
ORMP - CRDF
39%
Loosely correlated
+0.36%
NRIX - CRDF
37%
Loosely correlated
-3.31%
ABSI - CRDF
37%
Loosely correlated
+0.16%
SYRE - CRDF
35%
Loosely correlated
-0.91%
More